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CytoskeletonIn ischemic retinopathies, underlying hypoxia drives abnormal neovascularization that damages retina and
causes blindness. The abnormal neovasculature is tortuous and leaky and fails to alleviate hypoxia, resulting
in more pathological neovascularization and retinal damage. With an established model of ischemic
retinopathy we found that calpain inhibitors, when administered in moderation, reduced architectural
abnormalities, reduced vascular leakage, and most importantly reduced retinal hypoxia. Mechanistically,
these calpain inhibitors improved stability and organization of the actin cytoskeleton in retinal endothelial
cells undergoing capillary morphogenesis in vitro, and they similarly improved organization of actin cables
within new blood vessels in vivo. Hypoxia induced calpain activity in retinal endothelial cells and severely
disrupted the actin cytoskeleton, whereas calpain inhibitors preserved actin cables under hypoxic conditions.
Collectively, these ﬁndings support the hypothesis that hyper-activation of calpains by hypoxia contributes
to disruption of the retinal endothelial cell cytoskeleton, resulting in formation of neovessels that are
defective both architecturally and functionally. Modest suppression of calpain activity with calpain inhibitors
restores cytoskeletal architecture and promotes formation of a functional neovasculature, thereby reducing
underlying hypoxia. In sharp contrast to “anti-angiogenesis” strategies that cannot restore normoxia and
may aggravate hypoxia, the therapeutic strategy described here does not inhibit neovascularization. Instead,
by improving the function of neovascularization to reduce underlying hypoxia, moderate calpain inhibition
offers a method for alleviating retinal ischemia, thereby suggesting a new treatment paradigm based on
improvement rather than inhibition of new blood vessel growth.Beth Israel Deaconess Medical
1 617 667 5766; fax: +1 617
enger).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Retinopathy is a leading cause of blindness. Retinopathy is initiated
by vessel loss resulting in retinal hypoxia that can provoke two
responses: revascularizationwith “normal” vessels that relieve hypoxia,
or revascularizationwith abnormal vessels that leak. The abnormal new
blood vessels in retinopathy apparently often persist, leading to
tractional retinal detachment, and blindness [1–4]. This persistence
suggests that hypoxia is not relieved, although this has not been shown
previously. Recent research in ischemic retinopathies has focused
primarily on suppression of new blood vessels, i.e. inhibition of
angiogenesis. However, such strategies are at cross-purposes with
alleviation of the underlying hypoxia that drives recurring cycles of
abnormal neovascularization. Moreover, “anti-angiogenesis” strategies
do not distinguish between normal and abnormal neovessels and
therefore can aggravate hypoxia. Thus, a more physiological anddesirable therapeutic strategy is to improve the function of retinal
neovessels that arise during retinopathies and thereby alleviate the
retinal hypoxia that drives pathological neovascularization anddestroys
retina.
To this end,we have sought to identify strategies for reducing retinal
hypoxia by improving the architecture and function of new blood
vessels. In particular, we have focused on strategies involving
pharmacological normalization of calpain activity. Calpains are intra-
cellular, calcium-dependent thiol proteases [5,6]; and, upon activation,
these widely expressed enzymes cleave a broad spectrum of function-
ally important intracellular protein targets [5] that regulate cytoskeletal
organization [7], cell adhesion [8–10], and cell migration [10–12].
Calpain activity is induced in hypoxic retina, and calpain hyper-
activation has been implicated in retinal pathology [13,14]. However,
the consequences of calpain inhibition for hypoxia-induced neovascu-
larization have not been investigated previously. As described here, our
studies with an established mouse model of ischemic retinopathy [15]
illustrate ﬁrst that neovessels do not relieve hypoxia and that
moderation of calpain activity offers a novel strategy for normalizing
pathological retinal neovascularization and restoring normal oxygena-
tion. Moreover, these studies identify previously unrecognized
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hypoxia, disruptionof the retinal endothelial cell cytoskeleton, defective
capillary morphogenesis, and unrelieved hypoxia.
2. Materials and methods
2.1. Oxygen-induced retinopathy
All protocols involving mice were approved by the Beth Israel
Deaconess Medical Center Institutional Animal Care and Use Com-
mittee. Retinopathy was induced by exposing 7-day-old (P7) C57BL/6
pups with their nursing mother (Jackson Laboratory) to 75% oxygen
for 5 days as previously described [15]. At day 12 (P12), the pups and
the mother were returned to normal room air (21% oxygen), resulting
in hypoxic retina and re-growth of new blood vessels. The calpain
inhibitors (Calbiochem), MDL 28170 (0.25 mg/kg), PD 150606
(1.0 mg/kg), ALLN (10 mg/kg) or control vehicle were administered
daily by intraperitoneal injection from days P12 to P16 or from days
P12 to P20, as indicated, with animals harvested at day P17 or P21 for
evaluation of retinal blood vessel architecture and function (below).
2.2. Analyses of retinal vascular coverage and pericyte association, vascular
leakiness, vascular perfusion, and hypoxia
Animals were sacriﬁced, eyes enucleated, whole mount retinas
prepared for analyses as described [16] with the following additions/
modiﬁcations. Following the ﬁxation for 1 h in 10% formalin at room
temperature, retinas were dissected, washed in PBS (three times),
blocked and permeabilized overnight in PBS buffer containing 0.5%
Triton X-100, 10% goat serum, and 0.02% sodium azide. For analyses of
vascular coverage, retinas were stained with TRITC-Lectin (from
Bandeiraea simplicifolia, Sigma). To assess for pericyte associationwith
the vessels, retinas were stained with NG2 antibody (Chemicon
International) followed by FITC-conjugated secondary antibody
(Santa Cruz Biotechnology). Analyses of vascular perfusion and leak
were performed employing lysine-ﬁxable 70-kDa FITC dextran
(10 mg/kg, Invitrogen) injected via the tail vein. Animals were
harvested after 10 min perfusion. To assess retinal hypoxia, Hypoxyp-
robe™-1 (pimonidazole 120 mg/kg, Natural Pharmacia International,
Inc.) was used instead of FITC-dextran, and it was administered 1 h
before harvest. Retinas were co-stained with FITC-Hypoxyprobe
antibody and TRITC-Lectin (B. simplicifolia) for assessment of hypoxia
and vasculature, respectively. For actin staining of whole mount
retina, ﬂuorescent Oregon Green-conjugated phalloidin (Invitrogen)
was employed at a concentration of 0.5 units/ml. Stained retinas were
visualized and photographed with a camera Leica DX-300 microscope
using 4×, 10× and 20× objectives.
Vascularparameterswere all quantiﬁed fromdigital images ofwhole
retinas. Measurement of retinal neovascularization (vascular coverage
and perfused neovasculature) and neovascular tuft formation was
performed as described previously [17]. Focal leakage points were
identiﬁed as “clouds” of 70 kDa FITC-dextran outside of vasculature and
counted manually. Hypoxia was quantiﬁed by measuring hypoxic area
and integrating measured hypoxic area with FITC-Hypoxyprobe signal
intensity.
2.3. Immunohistochemical staining of vascular tufts in cross-section
Neovascular tufts were identiﬁed and quantiﬁed as described
previously [15]. Eyes were enucleated, embedded in OCT medium,
and snap frozen in liquid nitrogen. Five-micrometer-thick sectionswere
cut and endothelial cells stained with CD31 (PECAM-1) antibody
(Pharmingen) followed by secondary antibody conjugated with
horseradish peroxidase. Antibody staining was visualized with DAB
substrate, and sectionswere counterstainedwith hematoxylin solution.2.4. Analyses of human retinal endothelial cells in 3D collagen-I
Human retinal microvascular endothelial cells (RMVEC, Cell-
Systems) were propagated in corresponding CS-C Complete Medium
Kit (Cell-systems) and used between passages 3 to 7. Capillary
morphogenesis assays were performed by “sandwiching” and
“overlaying” conﬂuent cell monolayers with rat tail collagen-I (BD
Biosciences), basically as described previously [18]. The sandwich-
type assay was performed in 12-well plates with 1.0 mg/ml collagen-I
in full medium. Calpain inhibitors at various concentrations or vehicle
were added for overnight incubation, prior to adding the upper layer
of collagen-I. Capillary morphogenesis was allowed to proceed for
16 h; the assay plates were ﬁxedwith 10% formalin for 1 h and stained
for F-actin with ﬂuorescent Oregon Green-conjugated phalloidin
(Invitrogen, ﬁnal concentration 0.5 units/ml) and subsequently
photographed.
For the “overlay” assay, calpain inhibitors were added and
incubated with cells in 24-well plates overnight. The next day, each
well was overlaid with 300μl of collagen-I at concentration of 0.5 mg/
ml in CS-C Medium (minus serum and growth factors, Cell-Systems),
togetherwith calpain inhibitors as indicated. Capillarymorphogenesis
was allowed to proceed for 4 h; cells were ﬁxed in 10% formalin for
10 min, permeabilized for 1 min with 0.02% Triton-X100 in PBS and
stained for F-actin (as above) or stained with antibody to α-tubulin
(Clone DM 1A, Sigma) followed by ﬂuorescent Texas-Red secondary
antibody (Jackson Immunoresearch).
Cord length, blind ends, and polygons were quantiﬁed using NIH
ImageJ software. Cord length was traced and measured through
freehand line selections. Blind ends and polygons were determined
with point selections. Measured parameters correspond to actual areas
of 0.8 mm2.
2.5. Calpain ﬂuorometric assay
Calpain activity was measured in live retinal MVECs with an
established ﬂuorescent calpain substrate 7-amino-4-chloromethylcou-
marin, t-BOC-L-leucyl-L-methionine amide (CMAC, t-BOC-Leu-Met;
from Invitrogen) [19]; and calpain inhibitors, as indicated, were used
to establish speciﬁcity. Cells were incubated with 20 μM for 15 min at
37 °C; cleavage product was measured with a SpectraMax M5
ﬂuorescent plate reader (excitation/emission 351/430) with SoftMax
Pro5 software (Molecular Devices, Sunnyvale, CA).
2.6. Statistical analyses
Findings are presented as mean±standard error. Statistical
analyses were performed with InStat 3 software for Macintosh. For
comparisons between two groups, we employed the two-tail Mann–
Whitney test, assuming unequal variances between the two groups
under comparison. For comparisons among multiple groups, data
were analyzed with ANOVA, followed by the Bonferroni post-test.
3. Results
3.1. Hypoxia-induced neovascularization fails to alleviate retinal hypoxia
With an established mouse model of retinopathy of prematurity
that exhibits pathological neovessels similar to those seen in ischemic
retinopathies [15], we ﬁrst established that neovessels are inefﬁcient
at relieving hypoxia in retina. Although long suspected, hypoxia in re-
vascularized retina has not been demonstrated previously. In this
retinopathymodel, regression of immature blood vessels is induced in
7 day post-partum (P7) mice with hyperoxia (75% O2) for 5 days. At
12 days post-partum (P12), animals are returned to room air,
resulting in retinal hypoxia and induction of HIF-regulated proteins
such as vascular endothelial growth factor (VEGF) [20–22] that induce
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(P17), retinal vasculature was stained with TRITC-lectin (B. simplici-
folia) and retinas were simultaneously evaluated for hypoxia with an
established immunohistochemical method (Hypoxyprobe™, pimoni-
dazole HCl). Avascular regions of retina were strongly hypoxic as
expected (Fig. 1); but hypoxia was equally severe in large neovascu-
larized regions exhibiting abnormal vascular architecture that
included vascular tufts, suggesting poor blood ﬂow in these areas.
Thus, well-vascularized regions of retina remained hypoxic at P17,
establishing that vascular re-growth, in response to hypoxia, failed to
restore normal oxygenation (Fig. 1).
3.2. Compounds that target either the active site or critical calcium-binding
domain of calpains improve re-vascularization of retina and reduce retinal
hypoxia
Next, we investigated the consequences of calpain inhibition for
hypoxia-induced retinal neovascularization. During the hypoxia-driven
re-vascularization phase (P12–P17), animals were treated systemically
once daily with calpain inhibitors at doses chosen to normalize rather
than strongly inhibit calpain activity (see below). After 5 days (P17),
retinas from treatment and control groups were analyzed and
compared. As shown following whole mount staining of retinal
vasculature with TRITC-lectin (B. simplicifolia), optimum doses of
calpain inhibitors MDL 28170 (calpain inhibitor III), PD150606, and
ALLN (calpain inhibitor I) each signiﬁcantly improved vascular re-
growth(illustrated in Fig. 2A, toppanels—red color; see quantiﬁcation in
Fig. 2B and optimum dose determination in Fig. 2C). Most importantly,
eachof these calpain inhibitors, atoptimumdoses, substantially reduced
retinal hypoxia (illustrated in Fig. 2A, middle panels—green color; see
quantiﬁcation in Fig. 2D). Retinal hypoxiawas reducedby50% relative to
controls at P17 and reducedN75% at P21 (quantiﬁed in Fig.2D;
illustrated in Supplementary Fig. 1). In control and calpain inhibitor
groups, the remaining avascular regions of retinawere strongly hypoxic
as expected (Fig. 2A, middle panels—green color); but hypoxia was
equally severe in large neovascularized regions of controls, consistent
with poor perfusion of abnormal blood vessels (Fig. 2A, left bottom
panel—yellow color). In sharp contrast, with optimum calpain inhibitor
treatment, hypoxia was almost entirely limited to the remainingFig. 1. Hypoxia-induced neovascularization fails to alleviate retinal hypoxia. Regression of im
5 days. At P12, animals are returned to room air, resulting in retinal hypoxia and induction
evaluated for hypoxia (green color) with Hypoxyprobe™, and retinal vasculature was staine
with green color representing non-vascularized regions with strong hypoxia (encircled with
hypoxic; red color represents vascularized regions that were not detectably hypoxic. To the r
retinal area within the box (note that these images are rotated 90° from the original). Vascula
separately in green color (H=strong hypoxia); and a merged image illustrating overlap be
(yellow color=overlap between vasculature and hypoxia). Scale bar, 200 μm.avascular area that was reduced relative to controls, and nearly all of
the vascularized area was non-hypoxic (Fig. 2A, right bottom panel—
note absence of yellow color). Thus, in the calpain inhibitor groups,
there was greatly reduced hypoxia associated with retinal neovascular-
ization indicating that appropriate doses of calpain inhibitors rendered
new blood vessels substantially more effective at reducing hypoxia.
These observations, combinedwithmeasured improvement in vascular
coverage (Fig. 2B), indicate that themarked overall reductions in retinal
hypoxia achieved with calpain inhibitors were the result of improved
neovascular function together with increased vascular coverage.
Importantly, apart from optimum dose that is dependent on
potency and pharmacokinetics, we observed no differences in
effectiveness of the calpain inhibitors used in these experiments
despite distinctly different chemistries. ALLN, like MDL 28170, is a
cell-permeable peptidometic inhibitor that targets the enzymatic site
(reviewed [24]), whereas PD150606 [25] is a cell-permeable α-
mercaptoacrylate that targets the calcium-binding domain critical for
calpain activity. All three compounds inhibit the principal calpain
isoforms found in retina: calpain I (μ-calpain) which is activated by
micromolar calcium, and calpain II (m-calpain) which is activated by
millimolar calcium [14]. Similar to other peptidyl calpain inhibitors,
MDL 28170 and ALLN also inhibit cathepsins due to the similarities in
the active sites of these proteases [24]. In contrast, PD150606 targets
the calpain calcium domain not found in cathepsins and, therefore, is
highly speciﬁc (N600-fold) for calpains in comparison with cathepsins
[25]. Because PD150606, ALLN, and MDL 28170 all yielded the same
outcome in these experiments, we conclude that inhibition of calpain
activity is the most likely mechanism through which each of these
compounds improved neovascularization and reduced retinal hypoxia.
Notably, while appropriately moderate doses of calpain inhibitors
improved vascular coverage, in all cases higher doses were inhibitory.
Maximal improvement in vascular re-growth (reduction in avascular
area) was observed with MDL 28170 administered i.p. daily at
0.25 mg/kg, but inhibition of neovascularization was observed with
daily doses of 0.5 mg/kg and higher (Fig. 2A top right panel and C).
With PD150606, optimum improvement in vascular re-growth was
observed with daily administrations i.p. of 1 mg/kg, and inhibition of
neovascularization was observed with daily administrations of
3.0 mg/kg. For ALLN the dose optimum was 10 mg/kg daily butmature blood vessels was induced in 7-day-old (P7) mice with hyperoxia (75% O2) for
of abnormal re-vascularization. After 5 days of re-vascularization (P17), retinas were
d with B. simplicifolia TRITC-lectin (red color). Left panel (retina): whole mount retina
blue lines); yellow color=(red+green) represents vascularized regions that remained
ight of the whole retina panel are three panels at higher magniﬁcation representing the
ture staining is shown separately in red color (VT=vascular tufts); hypoxia is shown in
tween a highly vascularized region with prominent vascular tufts and strong hypoxia
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animal health were observed at the optimal or inhibitory doses;
therefore, it is likely that inhibition of neovascularization with the
higher doses of inhibitors was not simply a consequence of adverse
effects on overall animal health. Thus, administration of calpain
inhibitors in moderation was essential to achieve improvement
rather than inhibition of retinal neovascularization.
3.3. Calpain inhibitors suppress formation of abnormal vascular tufts,
reduce vascular leak, and improve vascular perfusion by circulating
tracer
To examine neovascular architecture in greater detail, we
quantiﬁed abnormal vascular tufts in retinal ﬂat mounts and analyzed
vascular tufts in cross section. Optimum doses of calpain inhibitors
MDL 28170, PD 150606, and ALLN each markedly reduced the
formation of prominent abnormal vascular tufts within 5 days of
treatment (P17) (Fig. 3A, B). Also, we examined the effect of calpain
inhibitors on dysfunctional vascular leakage. Consistent with im-
proved vascular architecture and reduction in vascular tufts that often
leak, calpain inhibitors MDL 28170, PD150606, and ALLN each
markedly reduced focal leakage in retina within 5 days (P17)
(Fig. 3C, D). Finally, we tested simple perfusion of the retinal
vasculature with tracer injected intravenously. Consistent with
improved vascular re-growth and reduced hypoxia, calpain inhibitors
improved overall perfusion of retina with tracer at P17 (Fig. 3E, F). Not
surprisingly, improvement in tracer perfusion provided by calpain
inhibitors was somewhat modest in comparison with reduction of
hypoxia (Fig. 2). This is expected because perfusion with tracer does
not measure improvement in blood ﬂow. By contrast, reduction in
abnormal vascular tufts (Fig. 3A, B) and reduction in vascular leak
(Fig. 3C, D) each of which is expected to improve blood ﬂow, were
closely similar to reduction in hypoxia (Fig. 2).
3.4. Calpain inhibitors enhance capillary morphogenesis and organization
of the actin cytoskeleton; modest (30–35%) inhibition of calpain activity
provides optimal improvement
To investigate mechanism(s) by which calpain inhibitors improve
neovessel architecture, we examined retinal microvascular endothe-
lial cells (MVECs) undergoing capillary morphogenesis in vitro with
models previously shown to correlate with neovascular architecture
in vivo [26]. Conﬂuent human retinal MVECs were “overlaid” (Fig. 4A)
or “sandwiched” (Supplementary Fig. 2) with interstitial collagen type
I, which provoked organization of the endothelial cell monolayer into
solid pre-capillary cords that are the precursors to capillary-like tubes
with lumens (reviewed [27]). Calpain inhibitor MDL 28170 and
calpastatin peptide, a highly speciﬁc 27-residue cell-permeable
calpain inhibitory peptide representing the functional inhibitory
domain of the natural endogenous calpain inhibitor [24,28], each
improved organization of retinal MVECs into capillary cords, as
measured by increased cord length, reduced blind ends, and overall
network organization (polygons) (Fig. 4A, B; Supplementary Fig. 2).
These inhibitors also improved alignment of actin cables during cordFig. 2.Moderate doses of calpain inhibitors improve vascular re-growth and reduce retinal hypo
inhibitorMDL28170, beginningwith theonset of retinopathy for 5 days (P12–17).Wholemoun
note that MDL 28170 at 0.25 mg/kg improved vascular re-growth whereas 0.50 mg/kg did not
retinas were also stained for hypoxia with Hypoxyprobe™ (green, middle panels). Bottom pan
absence of neovasculature and yellow color (red+green) corresponds to abnormal vascularized
as determinedwith B. simplicifolia TRITC-lectin staining (Panel “A”, upper panels in red), followi
optimal doses, see (C) below (*pb0.05, n≥11 animals for each group). (C) Determination of
avascular area.Maximal improvement in retinal neovascularizationwas achievedwithoncedail
Panel A. Optimal once daily doses for PD150606 (1 mg/kg) and ALLN (10 mg/kg) were determ
achievedwith optimal once daily doses of calpain inhibitorsMDL 28170 (0.25 mg/kg), PD15060
17 (P17) or treated for 9 days and harvested at day 21 (P21), as indicated. Relative to time-mat
retinal area observed in whole mount retinas (**pb0.01, n≥9 animals for each group).formation (Fig. 4A, C; Supplementary Fig. 2) and prevented collapse of
microtubules at cell–cell junctions (Fig. 4C), consistent with increased
cord length and reduction in blind ends. Similarly, we found that
calpain inhibitors also improved organization of the actin cytoskel-
eton in newly formed blood vessels in vivo (Fig. 4D). Thus, these
experiments link calpain inhibition to improved cytoskeletal organi-
zation, improved capillary morphogenesis, and improved neovascular
architecture.
Findings that calpain inhibitors improve capillary morphogenesis
in vitro provided the opportunity to estimate the amount of calpain
inhibition required for optimal improvement. Dose experiments
established that MDL 28170 maximally improved capillary morpho-
genesis at 10 nM which is less than that required for half-maximum
inhibition of calpains [29,30] (Fig. 4E). Comparable improvement of
capillary morphogenesis was achieved with calpastatin peptide at
200 nM. With an established calpain ﬂuorescent substrate assay
applied to live retinal MVECs in culture, we determined that these
concentrations of inhibitors each corresponded to ~30–35% inhibition
of total calpain activity in retinal MVECs (Fig. 4F).
3.5. Hypoxia activates calpain in retinal endothelial cells and disrupts
the actin cytoskeleton
Because hypoxia is a key parameter in ischemic retinopathy, we also
investigated a possible relationship between hypoxia, calpain activity,
and cytoskeletal instability in retinal MVECs. Retinal MVECs were
subjected to hypoxia and calpain activity was assayed in live cells with
an established ﬂuorometric substrate in combination with calpain
inhibitors. We found signiﬁcant (~50%) induction of calpain substrate-
cleaving activity with hypoxia, and calpain inhibitors blocked this
activity (Fig. 5A). Most signiﬁcantly, we found that hypoxia severely
disrupted actin cables in retinal MVECs undergoing capillary morpho-
genesis and that calpain inhibitors not only restored the actin
cytoskeleton during hypoxia but also promoted coordinate alignment
of actin cables between neighboring MVECs within vascular network
(Fig. 5B). Therefore, these studies link hypoxia-induction of calpain
activity to destabilization of the actin cytoskeleton in retinal MVECs.
Also, these observations in vitro are consistent with our ﬁndings that
calpain inhibitors simultaneously reduce retinal hypoxia (Fig. 2) and
improve the vascular actin cytoskeleton of neovasculature in vivo
(Fig. 4D). Collectively, the in vitro and in vivo data indicate that calpain
inhibitors promote cytoskeletal stabilization directly in retinal MVECs
under both hypoxic (Fig. 5B) and normoxic (Fig. 4A, C) conditions. In
addition, by reducing retinal hypoxia (Fig. 2) and thereby reducing
hypoxia-induced calpain activity (Fig. 5A) that disrupts actin cables
(Fig. 5B), calpain inhibitor treatment likely provides further stabilization
of the endothelial cell cytoskeleton and neovascular networks.
4. Discussion
In this study, with a mouse model of retinopathy of pre-maturity
that exhibits the key vascular defects associated with ischemic
retinopathies, we found that administration of calpain inhibitors in
moderation profoundly improved neovascular architecture andxia associatedwith ischemic retinopathy. (A) Animalswere treatedwith vehicle or calpain
t retina vasculature at P17was stainedwithB. simplicifoliaTRITC-lectin (red, upper panels);
improve re-growth and insteadwas inhibitory (see Panel C for dose curve). Whole mount
els are merged images of the upper two panels; green color corresponds to hypoxia in the
area that is still severely hypoxic. Scale bar, 500 μm. (B) Quantiﬁcation of % avascular area,
ng treatmentwith vehicle control or calpain inhibitorsMDL 28170, PD150606, and ALLN at
optimal drug doses for improving vascular re-growth as determined by quantiﬁcation of
y administrationofMDL28170 at 0.25 mg/kg; higherdoseswere inhibitoryas illustrated in
ined as illustrated for MDL 28170. (D) Quantiﬁcation of reduction in hypoxic retinal area
6 (1 mg/kg), and ALLN (10 mg/kg). Animals were treated for 5 days and harvested on day
ched vehicle controls at P17 and P21, calpain inhibitors substantially reduced the hypoxic
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reduction in vascular leakage. Administration of calpain inhibitors
also signiﬁcantly improved vascular re-growth, as measured by
improved vascular coverage of retina. Most importantly, the im-provement in neovascularization provided by calpain inhibitors
resulted in marked reduction of underlying retinal hypoxia. Allevia-
tion of underlying retinal hypoxia is critically important because
hypoxia drives recurring pathological neovascularization, ultimately
Fig. 3.Moderate doses of calpain inhibitors reduce abnormal vascular tufts and reduce vascular leakiness associated with retinopathy and also improve vascular perfusion of retina.
Animals were treated with vehicle or optimal doses of calpain inhibitors (see Fig. 2) for 5 days beginning with the onset of retinopathy (P12) and harvested at P17. (A) Imaging of
vascular tufts. Upper panels: whole mount retina vasculature stained with B. simplicifolia TRITC-lectin. Lower panels: retina cross-sections stained for endothelial cells with CD31
antibody (brown color). Arrows denote vascular tufts. G=ganglion layer, I=inner nuclear layer, O=outer nuclear layer. Scale bars: upper panels, 200 μm; lower panels, 50 μm.
(B) Quantiﬁcation of vascular tufts in whole mount retinas at P17: calpain inhibitors MDL 28170, PD 150606, and ALLN similarly reduced% retina area containing vascular tufts
relative to controls (**pb0.01, n≥9 animals for each group). (C) Analyses of vascular leakiness. Left panel: typical vascular leaks (arrows) in whole mount retina of vehicle control of
animal perfused with FITC-dextran tracer. Right panel: typical absence of leak in whole mount retina of animal treated with calpain inhibitor MDL 28170. Scale bar, 100 μm.
(D) Quantiﬁcation of vascular leak in whole mount retinas. Relative to controls, calpain inhibitors MDL 28170, PD 150606, and ALLN similarly reduced # focal leakage points/retina
(**pb0.01, n≥9 animals for each group). (E) Analysis of retinal vascular perfusion: whole mounted retinal vasculature following live perfusion with FITC-labeled dextran tracer.
Scale bar, 500 μm. (F) Quantiﬁcation of % unperfused area following treatment with vehicle control or calpain inhibitors MDL 28170, PD150606, and ALLN (**pb0.01, n≥9 animals
for each group).
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Fig. 4. Calpain inhibitors improve organization and alignment of endothelial cell actin cables during capillary morphogenesis in vitro and neovascularization in vivo; optimal
improvement is achieved with 30–35% inhibition of calpain activity. (A) F-actin (stained with FITC-phalloidin) in retinal MVECs undergoing capillary morphogenesis in vitro in
response to overlay with collagen I. Scale bar, 25 μm. Calpain inhibitor doses: MDL 28170 (10 nM), calpastatin peptide (200 nM). (B) Calpain inhibitors improve capillary
morphogenesis in vitro as measured by increased cord length, increased formation of inter-connected polygon networks, and reduction in blind ends. ***pb0.001, n=21 for each
group; no signiﬁcant difference is observed between calpain inhibitors, calpastatin peptide and MDL 28170. (C) Consistent with reduction in blind ends during capillary
morphogenesis, calpain inhibitors simultaneously improve stability of actin and tubulin in vitro, particularly at cell/cell junctions (see arrows) that are critical for stable inter-
connection of vascular networks. Scale bar, 20 μm. (D) In vivo, during retinal neovascularization, calpain inhibitor MDL 28170 (0.25 mg/kg, once daily) improves organization and
alignment of vascular actin similar to ﬁndings in vitro. Animals were treated beginning with the onset of retinopathy for 5 days (P12–17), and whole mount retinas were stained for
F-actin with FITC-phalloidin. Scale bar: 25 μm. (E) Maximal improvement of capillary morphogenesis in vitro, as measured by closed polygons/microscopic ﬁeld, is achieved with
MDL 28170 at a concentration of 10 nM. Lower and higher concentrations are less effective or inhibitory (***pb0.001 for 10 nM in comparison with control and 100 nM dose; n≥15
for each group). Similarly, the optimum dose of calpastatin peptide was determined to be 200 nM. (F) Assay of calpain activity in live retinal MVECs; doses of calpain inhibitors MDL
28170 (10 nM) and calpastatin (200 nM) that provide maximal improvement of capillary morphogenesis in vitro correspond to 30–35% inhibition of calpain activity. *pb0.05.
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ably, in controls, much of the retinal area that experienced vascular
re-growth remained hypoxic, indicating that neovascularization per se
is insufﬁcient to alleviate hypoxia. The vascular architecture in these
hypoxic regions was highly abnormal, consistent with poor vascular
function. By contrast, revascularized regions of the retinas of animals
treated with optimally moderate doses of calpain inhibitors were
primarily normoxic. Thus, administration of calpain inhibitors
promoted re-growth of architecturally improved blood vessels thatalleviated retinal hypoxia, whereas vascular re-growth without such
treatment was comparatively inefﬁcient.
In retinopathies, including the mouse model of retinopathy
employed here, hypoxia induces expression of HIF-regulated cyto-
kines such as VEGF that drive neovascularization [1,20–23,31]. It
seems counterintuitive that hypoxia would induce a neovasculature
that is architecturally abnormal and leaky and, as shown here, unable
to restore normal oxygenation. Thus, the question arises as to why
retinal hypoxia induces an abnormal neovasculature. Two of our
Fig. 5. Hypoxia induces calpain activity and disassembles the actin cytoskeleton in retinalMVECs;moderate calpain inhibition restores actin cables in hypoxia. (A) RetinalMVECs cultured
in normoxia (21% O2) were subjected to hypoxia (5% O2) for 2 h in the presence or absence of calpain inhibitors (calpastatin 200 nM or MDL 28170, at doses indicated) and assayed for
calpain activity as described in Materials and methods. **pb0.01, n≥17. (B) The actin cytoskeleton of retinal MVECs undergoing capillary morphogenesis induced by collagen I was
visualized by staining with FITC-phalloidin. Cells were in normoxia (21% O2) or hypoxia (5% O2), and calpain inhibitors MDL 28170 (10 nM) or calpastatin (200 nM) were added, as
indicated. These calpain inhibitor doses aremoderate and inhibit calpain activity only partially (see Panel A). In comparisonwith cells in normoxia, actin cableswere nearly absent in cells
under hypoxic conditions. However, moderate doses of calpain inhibitors strongly restored actin cables in hypoxia and also promoted cable alignment. Scale bar: 20 μm.
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retinal neovascularization in response to hypoxia may be due, at
least in part, to hyper-activation of calpain. First, as summarized
above, moderate calpain inhibition improves hypoxia-induced neo-
vascular architecture and function in vivo; and secondly, hypoxia
induces calpain activity in retinal MVECs in vitro. Consistent with our
observations that hypoxia induces calpain activity in retinal MVECs,
calpain activation has been demonstrated previously in hypoxic retina
in vivo [13,14], and hypoxia has been shown also to activate calpain in
endothelial cells from lung [32] and umbilical vein [33].
Calpains cleave a large number of proteins that regulate cytoskeletal
architecture, including cytoskeletal elements and proteins that link
cytoskeleton to membrane [5,34,35]. In particular, our data indicate a
functional relationship between calpain activity and disruption of the
retinal MVEC cytoskeleton. We found that calpain inhibitors strongly
improved organization of actin cables and microtubules in retinal
MVECs during capillary morphogenesis in vitro. Furthermore, hypoxia
severely disrupted the actin cytoskeleton of retinal MVECs in vitro, andcalpain inhibitors restored actin cables. Similarly, we found that calpain
inhibitors strongly improved organization of the endothelial actin
cytoskeleton in newly formed blood vessels in vivo. Thus, it is likely that
improvement inneovascular architectureprovidedby calpain inhibitors
is attributable to improved cytoskeletal organization and/or stability.
Most importantly, our data illustrate that optimalmoderation of calpain
activity with calpain inhibitors restores cytoskeletal organization,
improves capillary morphogenesis, and promotes formation of a
functionally improved neovasculature that reduces underlying hypoxia.
Consequently, calpain inhibitors offer a treatment strategy for alleviat-
ing the persistent hypoxia that causes recurring cycles of abnormal
neovascularization.
It is important to emphasize that these studies identiﬁed moderate
inhibition rather than severe inhibition of calpain as important for
achieving vascular improvements in hypoxic retina. In vitro capillary
morphogenesis experiments indicated that optimal improvementswere
observed at 30–35% calpain inhibition. In experiments in vitro and in vivo
we observed inhibition of capillary morphogenesis and inhibition of
557M.V. Hoang et al. / Biochimica et Biophysica Acta 1812 (2011) 549–557neovascularization with calpain inhibitor doses higher than that
required for optimal improvement. Given the importance of calpain
activity for basic cellular functions, suppression of angiogenesis with
higher doses of calpain inhibitors is not surprising. For example,
inhibition of calpain activity can interfere with normal cell adhesion
and migration [8,36]; and, in mice, deletion of the small subunit that is
common to both calpain I and calpain II results in embryonic death at
mid-gestation [37]. Others have reported that calpain inhibition
suppresses angiogenesis in vivo [38], andblocks capillarymorphogenesis
in vitro [39]; and our ﬁndings with the higher doses of calpain inhibitors
are consistent with these previous observations. However, and most
importantly, experiments described here establish that daily adminis-
tration of calpain inhibitors at appropriately moderate doses improves
the function of neovessels rather than inhibits neovascularization.
Finally, in sharp contrast to “anti-angiogenesis” treatment strat-
egies such as those targeting VEGF or VEGF receptors (reviewed in
[40]), the calpain inhibitor strategy described here does not inhibit
angiogenesis but rather corrects pathological neovascularization to
reduce hypoxia. Inhibition of neovascularization cannot alleviate
underlying hypoxia; moreover, inhibition of VEGF or VEGF signaling
may harm neural retina that is VEGF-dependent [41]. Alleviation of
hypoxia is of paramount importance in ischemic retinopathy because
hypoxia destroys photoreceptors and ganglion cells and also drives
formation of a pathological, leaky vasculature that causes retinal
detachment and blindness [1–4]. Accordingly, appropriately moder-
ate calpain inhibition, to improve functional neovascularization and
thereby remedy underlying hypoxia, offers a distinct and rational
advantage over “anti-angiogenesis” strategies for treating ischemic
retinopathies. In addition, this strategy suggests a new therapeutic
paradigm for treating retinal ischemia, based on improvement rather
than antagonism of new blood vessel growth.
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at doi:10.1016/j.bbadis.2010.08.008.Acknowledgements
We thank the V. Kann Rasmussen Foundation for ﬁnancial support.
This work also was supported by NIH grants CA129339 and NS064498
(DRS), NIH grants EY017017 and EY017017-S (LEHS), The Roche
Foundation for Anemia Research (LEHS), and a Research to Prevent
Blindness Senior Investigator Award (LEHS).
References
[1] A.P. Adamis, L.P. Aiello, R.A. D'Amato, Angiogenesis and ophthalmic disease,
Angiogenesis 3 (1999) 9–14.
[2] N.D. Wangsa-Wirawan, R.A. Linsenmeier, Retinal oxygen: fundamental and
clinical aspects, Arch. Ophthalmol. 121 (2003) 547–557.
[3] R.F. Gariano, T.W. Gardner, Retinal angiogenesis in development and disease,
Nature 438 (2005) 960–966.
[4] J. Chen, L.E. Smith, Retinopathy of prematurity, Angiogenesis 10 (2007) 133–140.
[5] D.E. Goll, V.F. Thompson, H. Li,W.Wei, J. Cong, The calpain system, Physiol. Rev. 83
(2003) 731–801.
[6] K. Suzuki, S. Hata, Y. Kawabata, H. Sorimachi, Structure, activation, and biology of
calpain, Diabetes 53 (Suppl 1) (2004) S12–S18.
[7] D.A. Potter, J.S. Tirnauer, R. Janssen, D.E. Croall, C.N. Hughes, K.A. Fiacco, J.W. Mier,
M. Maki, I.M. Herman, Calpain regulates actin remodeling during cell spreading, J.
Cell Biol. 141 (1998) 647–662.
[8] S. Kulkarni, T.C. Saido, K. Suzuki, J.E. Fox, Calpainmediates integrin-induced signaling
at a point upstream of Rho familymembers, J. Biol. Chem. 274 (1999) 21265–21275.
[9] A. Bhatt, I. Kaverina, C. Otey, A. Huttenlocher, Regulation of focal complex
composition and disassembly by the calcium-dependent protease calpain, J. Cell
Sci. 115 (2002) 3415–3425.
[10] A. Glading, D.A. Lauffenburger, A. Wells, Cutting to the chase: calpain proteases in
cell motility, Trends Cell Biol. 12 (2002) 46–54.
[11] N. Dourdin, A.K. Bhatt, P. Dutt, P.A. Greer, J.S. Arthur, J.S. Elce, A. Huttenlocher,
Reduced cell migration and disruption of the actin cytoskeleton in calpain-
deﬁcient embryonic ﬁbroblasts, J. Biol. Chem. 276 (2001) 48382–48388.
[12] S.J. Franco, A. Huttenlocher, Regulating cell migration: calpains make the cut, J.
Cell Sci. 118 (2005) 3829–3838.
[13] E. Nakajima, L.L. David, C. Bystrom, T.R. Shearer, M. Azuma, Calpain-speciﬁc
proteolysis in primate retina: contribution of calpains in cell death, Investig.
Ophthalmol. Vis. Sci. 47 (2006) 5469–5475.[14] M. Azuma, T.R. Shearer, The role of calcium-activated protease calpain in
experimental retinal pathology, Surv. Ophthalmol. 53 (2008) 150–163.
[15] L.E. Smith, E. Wesolowski, A. McLellan, S.K. Kostyk, R. D'Amato, R. Sullivan, P.A.
D'Amore, Oxygen-induced retinopathy in the mouse, Investig. Ophthalmol. Vis.
Sci. 35 (1994) 101–111.
[16] R. D'Amato, E. Wesolowski, L.E. Smith, Microscopic visualization of the retina by
angiography with high-molecular-weight ﬂuorescein-labeled dextrans in the
mouse, Microvasc. Res. 46 (1993) 135–142.
[17] K.M. Connor, J.P. SanGiovanni, C. Lofqvist, C.M. Aderman, J. Chen, A. Higuchi, S.
Hong, E.A. Pravda, S. Majchrzak, D. Carper, A. Hellstrom, J.X. Kang, E.Y. Chew, N.
Salem Jr., C.N. Serhan, L.E. Smith, Increased dietary intake of omega-3-
polyunsaturated fatty acids reduces pathological retinal angiogenesis, Nat. Med.
13 (2007) 868–873.
[18] M.V. Hoang, D.R. Senger, In vivo and in vitro models of mammalian angiogenesis,
Meth. Mol. Biol. 294 (2005) 269–285.
[19] B.G. Rosser, G.J. Gores, Cellular in vivo assay of calpain activity using a ﬂuorescent
substrate. Application to study of anoxic liver injury, Meth. Mol. Biol. 144 (2000)
245–259.
[20] E.A. Pierce, R.L. Avery, E.D. Foley, L.P. Aiello, L.E. Smith, Vascular endothelial
growth factor/vascular permeability factor expression in a mouse model of retinal
neovascularization, Proc. Natl. Acad. Sci. USA 92 (1995) 905–909.
[21] D.T. Shima, A.P. Adamis, N. Ferrara, K.T. Yeo, T.K. Yeo, R. Allende, J. Folkman, P.A.
D'Amore, Hypoxic induction of endothelial cell growth factors in retinal cells:
identiﬁcation and characterization of vascular endothelial growth factor (VEGF)
as the mitogen, Mol. Med. 1 (1995) 182–193.
[22] J. Pe'er, D. Shweiki, A. Itin, I. Hemo, H. Gnessin, E. Keshet, Hypoxia-induced
expression of vascular endothelial growth factor by retinal cells is a common
factor in neovascularizing ocular diseases, Lab. Investig. 72 (1995) 638–645.
[23] G.S. Robinson, E.A. Pierce, S.L. Rook, E. Foley, R. Webb, L.E. Smith, Oligodeox-
ynucleotides inhibit retinal neovascularization in a murine model of proliferative
retinopathy, Proc. Natl. Acad. Sci. USA 93 (1996) 4851–4856.
[24] I.O. Donkor, A survey of calpain inhibitors, Curr. Med. Chem. 7 (2000) 1171–1188.
[25] K.K. Wang, R. Nath, A. Posner, K.J. Raser, M. Buroker-Kilgore, I. Hajimoham-
madreza, A.W. Probert Jr., F.W. Marcoux, Q. Ye, E. Takano, M. Hatanaka, M.
Maki, H. Caner, J.L. Collins, A. Fergus, K.S. Lee, E.A. Lunney, S.J. Hays, P. Yuen,
An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-
permeable calpain inhibitor and is neuroprotective, Proc. Natl. Acad. Sci. USA
93 (1996) 6687–6692.
[26] M.V. Hoang, M.C. Whelan, D.R. Senger, Rho activity critically and selectively
regulates endothelial cell organization during angiogenesis, Proc. Natl. Acad. Sci.
USA 101 (2004) 1874–1879.
[27] M.C. Whelan, D.R. Senger, Collagen I initiates endothelial cell morphogenesis by
inducing actin polymerization through suppression of cyclic AMP and protein
kinase A, J. Biol. Chem. 278 (2003) 327–334.
[28] M. Maki, H. Bagci, K. Hamaguchi, M. Ueda, T. Murachi, M. Hatanaka, Inhibition of
calpain by a synthetic oligopeptide corresponding to an exon of the human
calpastatin gene, J. Biol. Chem. 264 (1989) 18866–18869.
[29] W. Lubisch, H.P. Hofmann, H.J. Treiber, A. Moller, Synthesis and biological
evaluation of novel piperidine carboxamide derived calpain inhibitors, Bioorg.
Med. Chem. Lett. 10 (2000) 2187–2191.
[30] K.S. Lee, S.H. Seo, Y.H. Lee, H.D. Kim, M.H. Son, B.Y. Chung, J.Y. Lee, C. Jin, Y.S. Lee,
Synthesis and biological evaluation of chromone carboxamides as calpain
inhibitors, Bioorg. Med. Chem. Lett. 15 (2005) 2857–2860.
[31] A.P. Adamis, D.T. Shima, M.J. Tolentino, E.S. Gragoudas, N. Ferrara, J. Folkman, P.A.
D'Amore, J.W. Miller, Inhibition of vascular endothelial growth factor prevents
retinal ischemia-associated iris neovascularization in a nonhuman primate, Arch.
Ophthalmol. 114 (1996) 66–71.
[32] J. Zhang, J.M. Patel, E.R. Block, Hypoxia-speciﬁc upregulation of calpain activity
and gene expression in pulmonary artery endothelial cells, Am. J. Physiol. 275
(1998) L461–L468.
[33] Y. Aono, H. Ariyoshi, Y. Tsuji, A. Ueda, M. Tokunaga, M. Sakon, M. Monden,
Localized activation of m-calpain in human umbilical vein endothelial cells upon
hypoxia, Thromb. Res. 102 (2001) 353–361.
[34] P. Tompa, P. Buzder-Lantos, A. Tantos, A. Farkas, A. Szilagyi, Z. Banoczi, F. Hudecz,
P. Friedrich, On the sequential determinants of calpain cleavage, J. Biol. Chem. 279
(2004) 20775–20785.
[35] M. Pfaff, X. Du, M.H. Ginsberg, Calpain cleavage of integrin beta cytoplasmic
domains, FEBS Lett. 460 (1999) 17–22.
[36] A. Huttenlocher, S.P. Palecek, Q. Lu,W. Zhang, R.L. Mellgren, D.A. Lauffenburger, M.
H. Ginsberg, A.F. Horwitz, Regulation of cell migration by the calcium-dependent
protease calpain, J. Biol. Chem. 272 (1997) 32719–32722.
[37] J.S. Arthur, J.S. Elce, C. Hegadorn, K. Williams, P.A. Greer, Disruption of the
murine calpain small subunit gene, Capn4: calpain is essential for embryonic
development but not for cell growth and division, Mol. Cell. Biol. 20 (2000)
4474–4481.
[38] Y. Su, Z. Cui, Z. Li, E.R. Block, Calpain-2 regulation of VEGF-mediated angiogenesis,
FASEB J. 20 (2006) 1443–1451.
[39] R.J. Bodnar, C.C. Yates, A. Wells, IP-10 blocks vascular endothelial growth factor-
induced endothelial cell motility and tube formation via inhibition of calpain, Circ.
Res. 98 (2006) 617–625.
[40] F. Shojaei, N. Ferrara, Antiangiogenesis to treat cancer and intraocular neovascular
disorders, Lab. Investig. 87 (2007) 227–230.
[41] M. Saint-Geniez, A.S. Maharaj, T.E. Walshe, B.A. Tucker, E. Sekiyama, T. Kurihara, D.
C. Darland, M.J. Young, P.A. D'Amore, Endogenous VEGF is required for visual
function: evidence for a survival role on muller cells and photoreceptors, PLoS
ONE 3 (2008) e3554.
